Pharmacokinetics and pharmacodynamics of daptomycin in a clinical setting. Issue 2 (February 2020)

• Record Type: Journal Article
• Authors: Tsukada, Hiroko; Tsuji, Yasuhiro; Yamashina, Takuya; Tsuruta, Minako; Hiraki, Yoichi; Tsuruyama, Moeko; Ogami, Chika; Kawasuji, Hitoshi; Sakamaki, Ippei; Yamamoto, Yoshihiro
• Is Part Of: Journal of infection and chemotherapy. Volume 26:Issue 2(2020:Feb.)
• Page Start: 230
• Page End: 235
• Publication Date: 2020-02
• Subjects: Area under the concentration-time curve/minimum inhibitory concentration -- Clearance of daptomycin -- Daptomycin -- Methicillin-resistant Staphylococcus aureus -- Pharmacokinetics; DAP daptomycin -- CK creatine kinase; Chemotherapy -- Periodicals; Infection -- Periodicals; Communicable diseases -- Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1016/j.jiac.2019.08.017
• Languages: English
• ISSNs: 1341-321X

Abstract

Abstract: We investigated achievement of a target 24-h area under the concentration-time curve to minimum inhibitory concentration ratio (AUC/MIC) ≥666 and the factors influencing this ratio in patients who received daptomycin (DAP) for infectious disease treatment in a clinical setting. The target AUC/MIC was obtained in 6 patients (35.3%) at a 4–6 mg/kg dose (Group_4–6 mg/kg ) and in 4 (18.2%) at a >6 mg/kg dose (Group_>6 mg/kg ). There was a significant difference in clearance of DAP (CL_DAP ) between these groups, but no other difference in characteristics. Multiple linear regression analysis was performed for prediction of AUC ≥666 based on patient factors and the presence or absence of sepsis. In a stepwise analysis, serum creatinine (SCr) was a significant predictor of AUC, but this parameter explained only 13% of the variance in achievement of the target AUC. These results show that the target AUC/MIC may or may not be achieved at the doses used in Group_4–6 mg/kg and Group_>6 mg/kg . Receiver operating characteristic analysis suggested that a CL_DAP >0.450 L/hr may lead to failure to reach the target AUC/MIC. Therefore, regardless of dose, the efficacy of DAP should be monitored closely to prevent failure of infectious disease treatment, particularly because therapeutic drug monitoring of DAP is limited by difficulty measuring the DAP serum concentration at many medical facilities. Our findings are preliminary, and a further study is required to identify factors that increase CL_DAP and to enable dose adjustment of DAP.